-
-
-
-
-
-
-
Merck ends acquisition talks with Revolution Medicines - WSJ
-
-
-
-
-
-
-
Merck Recommends Rejection of Tutanota’s “Mini-Tender” Offer
-
-
-
-
-
-
-
Merck posts higher third-quarter sales as Keytruda offsets drop in HPV vaccine
-
-
-
-
-
-
-
Merck Completes Acquisition of Verona Pharma
-
-
-
-
-
-
-
UBS Reiterates Buy Rating on Merck (MRK)
-
-
-
-
-
-
-
Merck Announces First-Quarter 2025 Financial Results
-
-
-
-
-
-
-
Merck to Present New Data From GARDASIL®9 Studies Reinforcing the Importance of Gender-Neutral HPV Vaccination in Adults Up to Age 45 at the International Papillomavirus Conference (IPVC) 2024
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

